Co-Delivery Nanomicelles for Potentiating TNBC Immunotherapy by Synergetically Reshaping CAFs-Mediated Tumor Stroma and Reprogramming Immunosuppressive Microenvironment

References

• Bianchini G, Balko JM, Mayer IA, et al. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13(11):674–690. doi:10.1038/nrclinonc.2016.66
   PubMed Web of Science ®Google Scholar
• Keenan TE, Tolaney SM. Role of immunotherapy in triple-negative breast cancer. J Natl Compr Canc Netw. 2020;18(4):479–489. doi:10.6004/jnccn.2020.7554
   PubMed Web of Science ®Google Scholar
• Henriques B, Mendes F, Martins D. Immunotherapy in breast cancer: when, how, and what challenges? Biomedicines. 2021;9(11):1687. doi:10.3390/biomedicines9111687
   PubMed Web of Science ®Google Scholar
• Park M, Kim D, Ko S, et al. Breast cancer metastasis: mechanisms and therapeutic implications. Int J Mol Sci. 2022;23(12):6806. doi:10.3390/ijms23126806
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17(8):807–821. doi:10.1038/s41423-020-0488-6
   PubMed Web of Science ®Google Scholar
• Rømer AMA, Thorseth ML, Madsen DH. Immune modulatory properties of collagen in cancer. Front Immunol. 2021;12:791453. doi:10.3389/fimmu.2021.791453
   PubMed Web of Science ®Google Scholar
• Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 2010;16(11):2927–2931. doi:10.1158/1078-0432.CCR-09-2329
   PubMed Web of Science ®Google Scholar
• Mhaidly R, Mechta-Grigoriou F. Role of cancer-associated fibroblast subpopulations in immune infiltration, as a new means of treatment in cancer. Immunol Rev. 2021;302(1):259–272. doi:10.1111/imr.12978
   PubMed Web of Science ®Google Scholar
• Chen IX, Chauhan VP, Posada J, et al. Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer. Proc Natl Acad Sci U S A. 2019;116(10):4558–4566. doi:10.1073/pnas.1815515116
   PubMed Web of Science ®Google Scholar
• Mezzapelle R, Leo M, Caprioglio F, et al. CXCR4/CXCL12 activities in the tumor microenvironment and implications for tumor immunotherapy. Cancers. 2022;14(9):2314. doi:10.3390/cancers14092314
   PubMed Web of Science ®Google Scholar
• Zhou W, Guo S, Liu M, et al. Targeting CXCL12/CXCR4 axis in tumor immunotherapy. Curr Med Chem. 2019;26(17):3026–3041. doi:10.2174/0929867324666170830111531
   PubMed Web of Science ®Google Scholar
• Zeng Y, Li B, Liang Y, et al. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment. FASEB J. 2019;33(5):6596–6608. doi:10.1096/fj.201802067RR
   PubMed Web of Science ®Google Scholar
• De Vita A, Liverani C, Molinaro R, et al. Lysyl oxidase engineered lipid nanovesicles for the treatment of triple negative breast cancer. Sci Rep. 2021;11(1):5107. doi:10.1038/s41598-021-84492-3
   PubMed Web of Science ®Google Scholar
• Gabellone S, Piccinino D, Filippi S, et al. Lignin nanoparticles deliver novel thymine biomimetic photo-adducts with antimelanoma activity. Int J Mol Sci. 2022;23(2):915. doi:10.3390/ijms23020915
   PubMed Web of Science ®Google Scholar
• Xue J, Li R, Gao D, et al. CXCL12/CXCR4 axis-targeted dual-functional nano-drug delivery system against ovarian cancer. Int J Nanomedicine. 2020;15:5701–5718. doi:10.2147/IJN.S257527
   PubMed Web of Science ®Google Scholar
• Kim D, Lee SS, Moon H, et al. PD-L1 targeting immune-microbubble complex enhances therapeutic index in murine colon cancer models. Pharmaceuticals. 2020;14(1):6. doi:10.3390/ph14010006
   Web of Science ®Google Scholar
• Zhao R, Liu J, Li Z, et al. Recent advances in CXCL12/CXCR4 antagonists and nano-based drug delivery systems for cancer therapy. Pharmaceutics. 2022;14(8):1541. doi:10.3390/pharmaceutics14081541
   PubMed Web of Science ®Google Scholar
• Uthaman S, Huh KM, Park IK. Tumor microenvironment-responsive nanoparticles for cancer theragnostic applications. Biomater Res. 2018;22(1):22. doi:10.1186/s40824-018-0132-z
   PubMedGoogle Scholar
• Zhu SW, Ye M, Ma X, et al. pH-responsive nanoprodrugs combining a Src inhibitor and chemotherapy to potentiate antitumor immunity via pyroptosis in head and neck cancer. Acta Biomater. 2022;154:497–509. doi:10.1016/j.actbio.2022.10.051
   PubMed Web of Science ®Google Scholar
• Xie X, Chen Y, Chen Z, et al. Polymeric hybrid nanomicelles for cancer theranostics: an efficient and precise anticancer strategy for the codelivery of Doxorubicin/miR-34a and magnetic resonance imaging. ACS Appl Mater Interfaces. 2019;11(47):43865–43878. doi:10.1021/acsami.9b14908
   PubMed Web of Science ®Google Scholar
• Sokol M, Zenin V, Yabbarov N, et al. Validated HPLC method for paclitaxel determination in PLGA submicron particles conjugated with α-fetoprotein third domain: sample preparation case study. Ann Pharm Fr. 2021;79(5):500–510. doi:10.1016/j.pharma.2021.02.001
   PubMed Web of Science ®Google Scholar
• Bapatu HR, Maram RK, Murthy RS. Robust and rugged stability-indicating HPLC method for the determination of plerixafor and its related impurities in drug substances. J Chromatogr Sci. 2015;53(9):1432–1442. doi:10.1093/chromsci/bmv029
   PubMed Web of Science ®Google Scholar
• Liang Y, Su Z, Yao Y, et al. Preparation of pH sensitive pluronic-docetaxel conjugate micelles to balance the stability and controlled release issues. Materials. 2015;8(2):379–391. doi:10.3390/ma8020379
   PubMed Web of Science ®Google Scholar
• Su WT, Huang CC, Liu HW. Evaluation and preparation of a designed kartogenin Drug Delivery System (DDS) of hydrazone-linkage-based pH responsive mPEG-Hz-b-PCL nanomicelles for treatment of osteoarthritis. Front Bioeng Biotechnol. 2022;10:816664. doi:10.3389/fbioe.2022.816664
   PubMed Web of Science ®Google Scholar
• Mao C, Yeh S, Fu J, et al. Delivery of an ectonucleotidase inhibitor with ROS-responsive nanoparticles overcomes adenosine-mediated cancer immunosuppression. Sci Transl Med. 2022;14(648):eabh1261. doi:10.1126/scitranslmed.abh1261
   PubMed Web of Science ®Google Scholar
• Wang X, Wang F, Zhong M, et al. The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy. Mol Cancer. 2020;19(1):81. doi:10.1186/s12943-020-01200-x
   PubMed Web of Science ®Google Scholar
• Hayashi H, Nakagawa K. Combination therapy with PD-1 or PD-L1 inhibitors for cancer. Int J Clin Oncol. 2020;25(5):818–830. doi:10.1007/s10147-019-01548-1
   PubMed Web of Science ®Google Scholar
• Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16(9):582–598. doi:10.1038/nrc.2016.73
   PubMed Web of Science ®Google Scholar
• Feig C, Jones JO, Kraman M, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A. 2013;110(50):20212–20217. doi:10.1073/pnas.1320318110
   PubMed Web of Science ®Google Scholar
• Dituri F, Mancarella S, Serino G, et al. Direct and indirect effect of TGFβ on treg transendothelial recruitment in HCC tissue microenvironment. Int J Mol Sci. 2021;22(21):11765. doi:10.3390/ijms222111765
   PubMed Web of Science ®Google Scholar
• Timperi E, Gueguen P, Molgora M, et al. Lipid-associated macrophages are induced by cancer-associated fibroblasts and mediate immune suppression in breast cancer. Cancer Res. 2022;82(18):3291–3306. doi:10.1158/0008-5472.CAN-22-1427
   PubMed Web of Science ®Google Scholar
• Voron T, Marcheteau E, Pernot S, et al. Control of the immune response by pro-angiogenic factors. Front Oncol. 2014;4:70. doi:10.3389/fonc.2014.00070
   PubMedGoogle Scholar
• Rahma OE, Hodi FS. The intersection between tumor angiogenesis and immune suppression. Clin Cancer Res. 2019;25(18):5449–5457. doi:10.1158/1078-0432.CCR-18-1543
   PubMed Web of Science ®Google Scholar
• Jenkins L, Jungwirth U, Avgustinova A, et al. Cancer-associated fibroblasts suppress CD8+ T-cell infiltration and confer resistance to immune-checkpoint blockade. Cancer Res. 2022;82(16):2904–2917. doi:10.1158/0008-5472.CAN-21-4141
   PubMed Web of Science ®Google Scholar
• Najafi M, Farhood B, Mortezaee K. Extracellular matrix (ECM) stiffness and degradation as cancer drivers. J Cell Biochem. 2019;120(3):2782–2790. doi:10.1002/jcb.27681
   PubMed Web of Science ®Google Scholar
• Freeman P, Mielgo A. Cancer-associated fibroblast mediated inhibition of CD8+ cytotoxic t cell accumulation in tumours: mechanisms and therapeutic opportunities. Cancers. 2020;12(9):2687. doi:10.3390/cancers12092687
   PubMed Web of Science ®Google Scholar
• Jensen C, Nissen NI, Von Arenstorff CS, et al. Serological assessment of collagen fragments and tumor fibrosis may guide immune checkpoint inhibitor therapy. J Exp Clin Cancer Res. 2021;40(1):326. doi:10.1186/s13046-021-02133-z
   PubMed Web of Science ®Google Scholar
• Vogel A, Martin K, Soukup K, et al. JAK1 signaling in dendritic cells promotes peripheral tolerance in autoimmunity through PD-L1-mediated regulatory T cell induction. Cell Rep. 2022;38(8):110420. doi:10.1016/j.celrep.2022.110420
   PubMed Web of Science ®Google Scholar
• Kersten K, Hu KH, Combes AJ, et al. Spatiotemporal co-dependency between macrophages and exhausted CD8+ T cells in cancer. Cancer Cell. 2022;40(6):624–638.e9. doi:10.1016/j.ccell.2022.05.004
   PubMed Web of Science ®Google Scholar
• Mo W, Liu S, Zhao X, et al. ROS scavenging nanozyme modulates immunosuppression for sensitized cancer immunotherapy. Adv Healthc Mater. 2023;8:e2300191. doi:10.1002/adhm.202300191
   Google Scholar